Soluble ligands as drug targets.

Area of Science:

• Pharmacology
• Biochemistry
• Drug Discovery

Background:

• Traditionally, drug targets included receptors, enzymes, ion channels, and transporters.
• The emergence of antibody-based therapies has elevated soluble protein ligands, such as inflammatory cytokines, as key drug targets.
• This review focuses on drugs targeting ligands that have advanced into clinical development since 1992.

Purpose of the Study:

• To analyze drugs targeting soluble protein ligands that have reached clinical development.
• To identify trends in ligand characteristics, drug profiles, and therapeutic indications.
• To assess the impact of ligand-targeting drugs on modern medicine.

Main Methods:

• Systematic review of drugs targeting ligands in clinical development since 1992.
• Identification and analysis of 291 drugs targeting 99 unique ligands.
• Examination of trends in ligand types, drug classes, and associated diseases.

Main Results:

• 291 drugs targeting 99 unique ligands were identified.
• The number of FDA-approved ligand-targeting drugs and validated ligand targets has doubled in the last five years.
• Cytokines and growth factors constitute 70% of targeted ligands, primarily for inflammation, autoimmune disorders, cancer, and ophthalmological diseases.

Conclusions:

• Soluble protein ligands are a rapidly growing class of drug targets.
• Ligand-targeting drugs show significant promise in treating inflammatory, autoimmune, oncological, and ophthalmological conditions.
• The central role of cytokine and growth factor pathways in disease pathogenesis is underscored by these therapeutic advancements.